Centessa Pharmaceuticals (NASDAQ:CNTA) Now Covered by Piper Sandler

Research analysts at Piper Sandler began coverage on shares of Centessa Pharmaceuticals (NASDAQ:CNTA) in a research report issued to clients and investors on Monday,Benzinga reports. The firm set an “overweight” rating and a $38.00 price target on the stock. Piper Sandler’s price objective would indicate a potential upside of 160.45% from the company’s current price.

Other analysts have also issued research reports about the company. Morgan Stanley restated an “overweight” rating and set a $27.00 price target on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. Guggenheim reaffirmed a “buy” rating and set a $28.00 price target on shares of Centessa Pharmaceuticals in a research note on Wednesday, March 26th. Finally, TD Cowen assumed coverage on shares of Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They issued a “buy” rating on the stock. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $27.71.

Centessa Pharmaceuticals Price Performance

Centessa Pharmaceuticals stock opened at $14.59 on Monday. Centessa Pharmaceuticals has a 52-week low of $7.75 and a 52-week high of $19.09. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The firm’s fifty day moving average is $16.48 and its 200 day moving average is $16.44. The company has a market cap of $1.92 billion, a price-to-earnings ratio of -9.54 and a beta of 1.54.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its earnings results on Monday, March 24th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.04. Sell-side analysts forecast that Centessa Pharmaceuticals will post -1.6 EPS for the current fiscal year.

Insider Activity at Centessa Pharmaceuticals

In other news, General Counsel Iqbal J. Hussain sold 6,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $15.29, for a total transaction of $91,740.00. Following the transaction, the general counsel now directly owns 118,265 shares of the company’s stock, valued at approximately $1,808,271.85. This trade represents a 4.83 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Gregory M. Weinhoff sold 11,742 shares of the business’s stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $16.47, for a total value of $193,390.74. Following the completion of the sale, the insider now owns 159,782 shares of the company’s stock, valued at $2,631,609.54. The trade was a 6.85 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 260,168 shares of company stock worth $4,309,568 in the last 90 days. 11.59% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Centessa Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC raised its holdings in shares of Centessa Pharmaceuticals by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 57,257 shares of the company’s stock valued at $959,000 after acquiring an additional 660 shares in the last quarter. GAMMA Investing LLC increased its holdings in Centessa Pharmaceuticals by 29.1% during the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock valued at $64,000 after buying an additional 865 shares during the period. GF Fund Management CO. LTD. bought a new position in Centessa Pharmaceuticals in the fourth quarter worth approximately $31,000. Barclays PLC lifted its holdings in Centessa Pharmaceuticals by 1,414.9% during the fourth quarter. Barclays PLC now owns 5,302 shares of the company’s stock worth $89,000 after buying an additional 4,952 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its position in Centessa Pharmaceuticals by 39.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 18,909 shares of the company’s stock valued at $317,000 after acquiring an additional 5,316 shares in the last quarter. Institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.